<p>India's Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.</p>.<p><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-global-coronavirus-cases-cross-15-million-physical-court-hearings-in-india-ruled-out-for-at-least-4-weeks-864013.html"><strong>For latest updates on Coronavirus outbreak, click here</strong></a></p>.<p>About 70% of patients being treated by FabiFlu achieved "clinical cure" by the fourth day of the study, compared with about 45% seen in the group treated with standard supportive care, the company said in a statement</p>
<p>India's Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.</p>.<p><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-global-coronavirus-cases-cross-15-million-physical-court-hearings-in-india-ruled-out-for-at-least-4-weeks-864013.html"><strong>For latest updates on Coronavirus outbreak, click here</strong></a></p>.<p>About 70% of patients being treated by FabiFlu achieved "clinical cure" by the fourth day of the study, compared with about 45% seen in the group treated with standard supportive care, the company said in a statement</p>